A Selection of Recent Papers

Secondary Structure at a Hot Spot for DNA Methylation in DNA from Human Breast Cancers. J. CLARK, S.S. SMITH (Duarte, CA, USA)


Tissue Microarrays of Human Tumor Xenografts: Characterization of Proteins Involved in Migration and Angiogenesis for Applications in the Development of Targeted Anticancer Agents. V. SMITH, G.J. WIRTH, H.-H. FIEBIG, A.M. BURGER (Freiburg, Germany; Geneva, Switzerland; Detroit, MI, USA)

Ochratoxin A Lowers mRNA Levels of Genes Encoding for Key Proteins of Liver Metabolism. C. HUNDHAUSEN, C. BOESCH-SAADATMANDI, N. MATZNER, F. LANG, R. BLANK, S. WOLFFRAM, W. BLASCHEK, G. RIMBACH (Kiel; Tuebingen, Germany)

Immune Response Signatures of Benzo(a)pyrene Exposure in Normal Human Mammary Epithelial Cells in the Absence or Presence of Chlorophyllin. K. JOHN, C. KESHAVA, D.L. RICHARDSON, A. WESTON, J. NATH (Morgantown, WV, USA)

The Protein Expression of TRP-1 and Galectin-1 in Cutaneous Malignant Melanomas. Å. BOLANDER, M. AGNARSDÓTTIR, S. STRÖMBERG, F. PONTEN, P. HESSELIUS, M. UHLEN, M. BERGQVIST (Uppsala; Stockholm, Sweden)


Relative Quantification of Cytochrome P450 1B1 Gene Expression in Peripheral Leukocytes using LightCycler. S. HELMIG, B. HADZAAD, J. DOHREL, J. SCHNEIDER (Giessen, Germany)

Label-free Global Serum Proteomic Profiling Reveals Novel Celecoxib-modulated Proteins in Familial Adenomatous Polyposis Patients. N. FATMA, D. CHIELIUS, B.T. LUKE, M. YI, T. ZHANG, S. STAUFFER, R. STEPHENS, P. LYNCH, K. MILLER, T. GUSZCZYNSKI, D. BORING, P. GREENWALD, I.U. ALI (Bethesda; Frederick, MD; San Jose, CA; Houston, TX, USA)


Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. S.M. BOKOBZA, L. YE, H.E. KYNASTON, R.E. MANSEL, W.G. JIANG (Cardiff, UK)


Genomic Analysis of Prostate Cancer Stem Cells Isolated from a Highly Metastatic Cell Line. R.A. ROWEHL, H. CRAWFORD, A. DUFOUR, J. JU, G.I. BOTCHKINA (Stony Brook, NY, USA)
Instructions to Authors

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double- spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

**Tables.** Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)

2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.

3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2009 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
Interleukin-6 Augments Activation of Liver Regeneration in Porcine Model of Partial Portal Vein Ligation. V. LISKA, V. TRESKA, H. MIRKA, J. KOBR, R. SYKORA, T. SKALICKY, A. SUTNAR, J. BRUHA, O. FIALA, O. VYCITAL, A. CHLUMSKA, L. HOLUBEC, M. MATEJOVIC (Plzen, Czech Republic) 2371


A Novel Method to Display [gal α1, 3 gal] Antigens on Human Leukemic Cells for Preparation of Anti-leukemia Vaccines. K.J. POSEKANY, J.E. WILEY, G.A. GAGNON (Greenville, NC, USA) 2387


Antioxidant and Cyclooxygenase-2-Inhibiting Activity of 4,4′-Biphenol, 2,2′-Biphenol and Phenol. Y. MURAKAMI, H. ISHII, S. HOSHINA, N. TAKADA, A. UEKI, S. TANAKA, Y. KADOMA, S. ITO, M. MACHINO, S. FUJISAWA (Saitama; Tokyo, Japan) 2403

The Sonodynamic Antitumor Effect of Methylene Blue on Sarcoma 180 Cells In Vitro. C. KOMORI, K. OKADA, K. KAWAMURA, S. CHIDA, T. SUZUKI (Akita, Japan) 2411

Apurinic/Apyrimidinic Endonuclease (APE1) Gene Polymorphisms and Lung Cancer Risk in Relation To Tobacco Smoking. B. AĞAÇHAN, Ö. KUÇUKHUSEYİN, P. AKSOY, A. TURNA, İ. YAYLIM, U. GÖRÜMÜŞ, A. ERGEN, Ü. ZEYBEK, B. DALAN, T. ISBIR (Istanbul, Turkey) 2417

* Review (pages 1909, 2031, 2127)
Selective Activity Against Proliferating Tumor Endothelial Cells by CVX-22, A Thrombospondin-1 Mimetic CovX-Body™. J. CORONELLA, L. LI, K. JOHNSON, S. PIRIE-SHEPHERD, G. ROXAS, N. LEVIN (San Diego, CA, USA) ................................................................. 2243

The RING Finger Protein11 Binds to Smad4 and Enhances Smad4-dependant TGF-β Signalling. P.B. AZMI, A.K. SETH (Toronto, ON, Canada) .................................................................................................................. 2253

Estimation of Relationship Between the Structure of 1,2,3,4-Tetrahydroisoquinoline Derivatives Determined by a Semiempirical Molecular-Orbital Method and their Cytotoxicity. M. ISHIHARA, H. HATANO, M. KAWASE, H. SAKAGAMI (Saitama; Ehime, Matsuyama, Japan) ............................................................... 2265

The Characterisation of Flavone-DNA Isoform Interactions as a Basis for Anticancer Drug Development. P.A. RAGAZZON, T. BRADSHAW, C. MATTHEWS, J. ILEY, S. MISSAILIDIS (Milton Keynes, UK) .................................................. 2273

Structure-activity Studies of the Binding of the Flavonoid Scaffold to DNA. P.A. RAGAZZON, J. ILEY, S. MISSAILIDIS (Milton Keynes, UK) ................................................................................................................ 2285

Epigenetic Modifiers Exacerbate Oxidative Stress in Renal Proximal Tubule Cells. E. NADASI, J.S. CLARK, I. SZANYI, T. VARIAS, I. EMBER, R. BALIGA, I. ARANY (Budapest; Pecs, Hungary; Jackson, MS, USA) ............ 2295

Black Tea Polyphenols Target Matrix Metalloproteinases, RECK, Proangiogenic Molecules and Histone Deacetylase in a Rat Hepatocarcinogenesis Model. R.S. MURUGAN, G. VINOTHINI, Y. HARÁ, S. NAGINI (Tamil Nadu, India; Tokyo, Japan) ........................................................................................................ 2301


A Role for the Substance P/NK-1 Receptor Complex in Cell Proliferation in Oral Squamous Cell Carcinoma. S. BRENER, M.A. GONZÁLEZ-MOLES, D. TOSTES, F. ESTEBAN, J.A. GIL-MONTOYA, I. RUIZ-ÁVILA, M. BRAVO, M. MUÑOZ (Sao Paulo, Brazil; Granada; Sevilla; Jaen, Spain) ............................................................................................................... 2323

IL-6 and PPARγ Signalling in Human PC-3 Prostate Cancer Cells. N. PITULIS, E. PAPAGEORGIOU, R. TENTA, P. LEMBESSION, M. KOUTSILIERIS (Athens, Greece) ........................................................................................................... 2331

Proving Tumour Cells by Acute Nutritional/Energy Deprivation as a Survival Threat: A Task for Microscopy. H.A. JANÉCKOVA, P. VESELY, R. CHMELÍK (Brno; Prague, Czech Republic) ........................................................................................................ 2339

Breast Tumor Cells Transendothelial Migration Induces Endothelial Cell Anoikis Through Extracellular Matrix Degradation. N. PEYRI, M. BERARD, F. FAUVEL-LAFEVE, V. TROCHON, B. ARBEILLE, H. LU, C. LEGRAN, M. CREPIN (Paris; Tours; Bobigny, France) ........................................................................................................ 2347

Expression of HMGA2-LPP and LPP-HMGA2 Fusion Genes in Lipoma: Identification of a Novel Type of LPP-HMGA2 Transcript in Four Cases. T. KUBO, Y. MATSUI, N. NAKA, N. ARAKI, T. GOTO, K. YUKATA, K. ENDO, N. YASUI, A. MYOUI, H. KAWABATA, H. YOSHIIKA, T. UEDA (Tokushima; Osaka, Japan) ....... 2357


Contents continued on the preceding page
Mechanisms of Escape from Trastuzumab-mediated ADCC in Esophageal Squamous Cell Carcinoma: Relation to Susceptibility to Perforin-granzyme. Y. KAWAGUCHI, K. KONO, Y. MIZUKAMI, K. MIMURA, H. FUJII (Yamanashi, Japan) ................................................................. 2137

The Hedgehog Signaling Pathway Plays an Essential Role in Maintaining the CD44\(^+\)CD24\(^–\)/low Subpopulation and the Side Population of Breast Cancer Cells. H. TANAKA, M. NAKAMURA, C. KAMEDA, M. KUBO, N. SATO, S. KUROKI, M. TANAKA, M. KATANO (Fukuoka, Japan) ................................................................. 2147

Antitumor Activity of a Selectively Replication Competent Herpes Simplex Virus (HSV) with Enzyme Prodrug Therapy. L. BRAIDWOOD, P.D. DUNN, S. HARDY, T.R. EVANS, S.M. BROWN (Glasgow, UK) ................................................................. 2159

Differential Effects of Aromatase Inhibitors and Antiestrogens on Estrogen Receptor Expression in Breast Cancer Cells. M. SMOLLICH, M. GÖTTE, J. FISCHGRÄBE, I. RADKE, L. KIESEL, P. WÜLFING (Münster, Germany) ................................................................. 2167

Demonstration of the Activity of P-glycoprotein by a Semi-automated Fluorometric Method. G. SPENGLER, M. VIVEIROS, M. MARTINS, L. RODRIGUES, A. MARTINS, J. MOLNAR, I. COUTO, L. AMARAL (Lisboa; Caparica, Portugal; Szeged, Hungary) ................................................................. 2173

(–)-Gossypol Reduces Invasiveness in Metastatic Prostate Cancer Cells. Y.-W. HUANG, L.-S. WANG, M.K. DOWD, P.J. WAN, Y.C. LIN (Columbus, OH; New Orleans, LA, USA) ................................................................. 2179

Expression of Eras Oncogene in Gastric Carcinoma. R. KAIZAKI, M. YASHIRO, O. SHINTO, K. YASUDA, T. MATSUZAKI, T. SAWADA, K. HIRAKAWA (Osaka, Japan) ................................................................. 2189

Riluzole Induces Apoptotic Cell Death in Human Prostate Cancer Cells via Endoplasmic Reticulum Stress. K. AKAMATSU, M.-A. SHIBATA, Y. ITO, Y. SOHMA, H. AZUMA, Y. OTSUKI (Osaka; Tokyo, Japan) ............. 2195

Osteopontin Modulates Malignant Pleural Mesothelioma Cell Functions In Vitro. R. OHASHI, K. TAJIMA, F. TAKAHASHI, R. CUI, T. GU, K. SHIMIZU, K. NISHIO, K. FUKUOKA, T. NAKANO, K. TAKAHASHI (Tokyo; Osaka; Hyogo, Japan) ................................................................. 2205


Expression of Bone Morphogenetic Proteins in Giant Cell Tumor of Bone. N. KUDO, A. OGOSE, T. ARIIZUMI, H. KAWASHIMA, T. HOTTA, H. HATANO, T. MORITA, M. NAGATA, Y. SIKI, A. KAWAI, Y. HOTTA, M. HOSHINO, N. ENDO (Niigata; Tokyo, Japan) ................................................................. 2219

Frequent Methylation of Vimentin in Well-differentiated Gastric Carcinoma. Y.-H. KITAMURA, A. SHIRAHATA, M. SAKATA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI (Yokohama, Japan) ................................................................. 2227

Methylation of HACE1 in Gastric Carcinoma. M. SAKATA, Y.-H. KITAMURA, K. SAKURABA, T. GOTO, H. MIZUKAMI, M. SAIITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, Y. SANADA, K. HIBI (Yokohama, Japan) ................................................................. 2231


Significant Association of Ku80 Single Nucleotide Polymorphisms with Colorectal Cancer Susceptibility in Central Taiwan. M.-D. YANG, Y.-M. HSU, Y.-S. KUO, H.-S. CHEN, C.-L. CHANG, C.-N. WU, C.-H. CHANG, Y.-M. LIAO, H.-C. WANG, M.-F. WANG, D.-T. BAU (Taichung, Taiwan, ROC) ................................................................. 2239

Contents continued on the preceding page

Promoter Demethylation of WIF-1 by Epigallocatechin-3-gallate in Lung Cancer Cells. Z. GAO, Z. XU, M.-S. HUNG, Y.-C. LIN, T. WANG, M. GONG, X. ZHI, D.M. JABLON, L. YOU (Beijing, China; San Francisco, CA, USA; Chiayi, Taiwan, ROC) ................................................................. 2025

* Review: Heat-shock Protein 90 (Hsp90) as a Molecular Target for Therapy of Gastrointestinal Cancer. C. MOSE, S.A. LANG, O. STOELTZING (Regensburg; Mainz, Germany) .............................................................. 2031

Identification of αvβ6-Positive Stem Cells in Oral Squamous Cell Carcinoma. D. DANG, D.M. RAMOS (San Francisco, CA, USA) ................................................................. 2043

Decreased Levels of Both Stat1 and Stat3 in T Lymphocytes from Mice Bearing Mammary Tumors. M.E. HANDEL-FERNANDEZ, D. ILKOVITCH, V. IRAQVARAPU-CHARYULU, L.M. HERBERT, D.M. LOPEZ (Miami; Boca Raton, FL, USA) ................................................................. 2051

Chemopreventive Effect of 4-[3,5-Bis(trimethylsilyl) benzamido] Benzoic Acid (TAC-101) on MNU-induced Colon Carcinogenesis in a Rat Model. Y. NAKAYAMA, Y. INOU, N. MINAGAWA, K. ONITSUKA, J. NAGATA, K. SHIBAO, K. HIRATA, T. SAKO, N. NAGATA, K. YAMAGUCHI (Kita-Kyushu; Joetsu, Japan) ................................................................. 2059

In Vitro and In Vivo Effects of CpG-Oligodeoxynucleotides (CpG-ODN) on Murine Transitional Cell Carcinoma and on the Native Murine Urinary Bladder Wall. P.J. OLBERT, A.J. SCHRADE, C. SIMON, A. DALPKE, P. BARTH, R. HOFMANN, A. HEGELE (Marburg; Heidelberg, Germany) ................................................................. 2067

Cytoplasmic Accumulation of Glycogen Synthase Kinase-3β Is Associated with Aggressive Clinicopathological Features in Human Prostate Cancer. R. LI, S. ERDAMAR, H. DAI, M. SAYEEDUDDIN, A. FROLOV, T.M. WHEELER, G.E. AYALA (Houston, TX, USA; Istanbul, Turkey) ................................................................. 2077

Molecular Mechanisms of Sequence-dependent Antitumor Effects of SN-38 and 5-Fluorouracil Combination Therapy against Colon Cancer Cells. S. TORIGOE, Y. OGATA, K. MATONO, K. SHIROUZU (Kurume, Japan) ................................................................. 2083


Improvement of Biodistribution and Therapeutic Index via Increase of Polyethylene Glycol on Drug-carrying Liposomes in an HT-29/luc Xenografted Mouse Model. T.-H. CHOW, Y.-Y. LIN, J.-J. HWANG, H.-E. WANG, Y.-L. TSENG, S.-J. WANG, R.-S. LIU, W.-J. LIN, C.-S. YANG, G. TING (Taipei; Taoyuan, Taiwan, ROC) ................................................................. 2111


* Review: Proton Transport Inhibitors as Potentially Selective Anticancer Drugs. S. HARGUINDEY, J.L. ARRANZ, M.L. WAHL, G. ORIVE, S.J. RESHKIN (Vitoria, Spain; Durham, NC, USA; Bari, Italy) ................................................................. 2127

Contents continued on the preceding page
Cleavage of the Ewing Tumour-specific EWSR1-FLI1 mRNA by Hammerhead Ribozymes. R. HÜHN, M.S. STAEGE, M. HESSE, B. LIEBIG, S.E.G. BURDACH (Halle; München, Germany) ................................................. 1901

* Review; Tissue Transglutaminase Promotes or Suppresses Tumors Depending on Cell Context. A. CHHABRA, A. VERMA, K. MEHTA (Houston, TX, USA) .......................................................................................... 1909

5-Hydroxymethylfurfural and 5-Sulfooxymethylfurfural Increase Adenoma and Flat ACF Number in the Intestine of Min/+ Mice. C. SVENDSEN, T. HUSØY, H. GLATT, J.E. PAULSEN, J. ALEXANDER (Oslo, Norway; Nuthetal, Germany) .......................................................... 1921

Conversion from Calcineurin Inhibitors to Sirolimus Reduces Vascularization and Thickness of Post-transplant Cutaneous Squamous Cell Carcinomas. A.-L. RIVAL-TRINGALI, S. EUVRARD, E. DECULLIER, A. CLAUDY, M. FAURE, J. KANITAKIS (Lyon, France) ............................................................ 1927

Spontaneous Regression of Human Cancer Cells In Vitro: Potential Role of Disruption of Cdk1/Cdk4 Co-expression. H. WARENIUS, L. KYRITSI, I. GRIERSON, A. HOWARTH, L. SEABRA, M. JONES, C. THOMAS, P. BROWNING, R. WHITE (Southampton; Wirral; Liverpool; Surrey; Manchester; Sheffield, UK; Ermoupolis, Greece) .......................................................................................... 1933

Inhibition of IGF-I Receptor Signaling in Combination with Rapamycin or Temsirolimus Increases MYC-N Phosphorylation. D.W. COULTER, M.B. WILKIE, B.M. MOATS-STAATS (Omaha, NE; Chapel Hill, NC, USA) ............................................................................................................................. 1943


Ribavirin Acts via Multiple Pathways in Inhibition of Leukemic Cell Proliferation. S. KÖKÉNY, J. PAPP, G. WEBER, T. VASZKÓ, P. CARMONA-SAEZ, E. OLÁH (Budapest, Hungary; Indianapolis, IN, USA; Madrid, Spain) ........................................................................................................ 1971


Impact of Tumor Cell VEGF Expression on the In Vivo Efficacy of Vandetanib (ZACTIMA™; ZD6474). D.W. SIEMANN, C.M. NORRIS, A. RYAN, W. SHI (Gainesville, FL, USA; Cheshire, UK) .............................................................. 1987

Assessment of Erlotinib in Chemoresponse Assay. S.D. RICE, J.E. BUSH, S.L. BROWER (Pittsburgh, PA, USA) ............................................................................................................................. 1993


14-3-3σ-Dependent Resistance to Cisplatin. Z. HAN, K. DIMAS, X. TIAN, Y. WANG, H. HEMMI, K. YAMADA, N. KATO, P. PANTAZIS, R.J. RAMANUJAM, S. ANANT, J.H. WYCHE, C.W. HOUCHE (New York, NY; Oklahoma City, OK; Minneapolis, MN, USA; Athens, Greece; Tokyo, Japan) ........................................................................................................ 2009

Contents continued on the preceding page